Tempus
Tempus AI Acquires Clinical Trial Patient Matching Firm Deep 6 AI
Pasadena, California-based Deep 6 AI matches patients to clinical trials by mining real-time structured and unstructured electronic medical record data.
Tempus, IFLI Partner to Accelerate Development of Follicular Lymphoma Therapies
The collaboration will involve making a real-world multimodal dataset available in Tempus' Lens platform that researchers can use to accelerate treatment development.
Tempus, Genialis Partner to Develop RNA-Based Cancer Biomarker Algorithms
Genialis will use Tempus' multimodal dataset to develop new RNA-based algorithms for a variety of cancers.
Personalis, Tempus Expand MRD Diagnostics Partnership to Include Biopharma
Tempus will now offer Personalis' NeXT Personal Dx minimal residual disease assay to pharmaceutical and biotech customers.
Lung Cancer Study Suggests Concurrent RNA, DNA Testing Picks up Actionable SVs
RNA sequencing unearthed actionable structural variants missed with DNA-only sequencing based on tumor assays on 5,570 advanced non-small cell lung cancer cases.